Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Baricitinib may effectively treat nail changes in alopecia areata.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Baricitinib is effective as a treatment for severe hair loss.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.